Backed by Science

Luminopia™ One is an digital therapeutic developed closely with leading physicians and neuroscientists and builds upon years of published research. Although Luminopia One has not yet been approved by the FDA, several clinical trials conducted on the therapeutic have demonstrated its potential to be an engaging and effective at-home treatment for amblyopia.

Supporting scientific literature

Digital Therapeutic Improves Visual Acuity and Encourages High Adherence in Amblyopic Children in Open-Label Pilot Study


Journal of AAPOS. In Press

Improved adherence and treatment outcomes with an engaging, personalized digital therapeutic in amblyopia


Scientific Reports 2020;10:8328.

Novel digital therapeutic improves visual acuity and encourages high adherence in amblyopic children


Journal of AAPOS 2019;23(4):E10.